- Home
- PRAX vs TYRA Comparison
PRAX vs TYRA Comparison
Compare PRAX & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- TYRA
- Stock Information
- Founded
- PRAX 2015
- TYRA 2018
- Country
- PRAX United States
- TYRA United States
- Employees
- PRAX N/A
- TYRA N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- PRAX Health Care
- TYRA Health Care
- Exchange
- PRAX Nasdaq
- TYRA Nasdaq
- Market Cap
- PRAX 1.2B
- TYRA 1.3B
- IPO Year
- PRAX 2020
- TYRA 2021
- Fundamental
- Price
- PRAX $74.92
- TYRA $25.86
- Analyst Decision
- PRAX Strong Buy
- TYRA Strong Buy
- Analyst Count
- PRAX 9
- TYRA 4
- Target Price
- PRAX $144.11
- TYRA $31.00
- AVG Volume (30 Days)
- PRAX 295.5K
- TYRA 185.7K
- Earning Date
- PRAX 11-05-2024
- TYRA 11-05-2024
- Dividend Yield
- PRAX N/A
- TYRA N/A
- EPS Growth
- PRAX N/A
- TYRA N/A
- EPS
- PRAX N/A
- TYRA N/A
- Revenue
- PRAX $1,771,000.00
- TYRA N/A
- Revenue This Year
- PRAX N/A
- TYRA N/A
- Revenue Next Year
- PRAX N/A
- TYRA N/A
- P/E Ratio
- PRAX N/A
- TYRA N/A
- Revenue Growth
- PRAX 20.97
- TYRA N/A
- 52 Week Low
- PRAX $13.01
- TYRA $10.38
- 52 Week High
- PRAX $75.73
- TYRA $27.18
- Technical
- Relative Strength Index (RSI)
- PRAX 71.35
- TYRA 67.74
- Support Level
- PRAX $60.73
- TYRA $20.30
- Resistance Level
- PRAX $65.87
- TYRA $22.21
- Average True Range (ATR)
- PRAX 3.85
- TYRA 1.46
- MACD
- PRAX 1.22
- TYRA 0.25
- Stochastic Oscillator
- PRAX 96.03
- TYRA 81.45
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).